Skip to content

Infliximab

Remicade (infliximab) is an antibody pharmaceutical. Infliximab was first approved as Remicade on 1998-08-24. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis in the USA. It has been approved in Europe to treat ankylosing spondylitis, crohn disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
Trade Name Remicade
Common Name Infliximab
ChEMBL ID CHEMBL1201581
Indication ankylosing spondylitis, crohn disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
Drug Class Monoclonal antibodies: chimeric, immunomodulating
Infliximab
Get full access now